Clinical Trial Detail

NCT ID NCT02588261
Title A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

lung non-small cell carcinoma

Therapies

Naquotinib

Gefitinib

Erlotinib

Age Groups: adult

No variant requirements are available.